Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ventyx Biosciences
Biotech
Lilly buys inflammation biotech Ventyx for $1.2B
Ventyx achieved its goal of securing Big Pharma commitment to its pipeline, with Lilly swooping in to buy the inflammation biotech for $1.2 billion.
James Waldron
Jan 8, 2026 7:01am
Ventyx's CV drug rapidly reduces cardio risk biomarker
Oct 23, 2025 9:45am
Ventyx posts Parkinson's data ahead of potential Sanofi talks
Jun 17, 2025 9:05am
Sanofi makes $27M equity investment in Ventyx
Sep 23, 2024 11:24am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
